Drugs / Visio-AMTRIX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05191628 | Jun 2020 → Oct 2022 | macular holes, retinal detachment | TBF Genie Tissulaire | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT06450470 | Nov 2024 → Nov 2025 overdue | keratoconus | TBF Genie Tissulaire | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visio-AMTRIX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06450470 ↗ |
| Modality | Other / unclassified | “Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane” NCT05191628 ↗ |
| Route | Other | “placed by the investigator during macular hole surgery” NCT05191628 ↗ |